AEON Biopharma, Inc. financial data

Symbol
AEON on NYSE
Industry
Pharmaceutical Preparations
Location
5 Park Plaza, Suite 1750, Irvine, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Priveterra Acquisition Corp. (to 7/24/2023)
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 55.3 % +393%
Debt-to-equity -109 % -93.3%
Return On Equity 161 %
Return On Assets -2.17K % -108229%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39.5M shares
Common Stock, Shares, Outstanding 39.1M shares
Entity Public Float 14.2M USD
Common Stock, Value, Issued 4K USD
Weighted Average Number of Shares Outstanding, Basic 38.8M shares -72%
Weighted Average Number of Shares Outstanding, Diluted 38.8M shares -72%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.44M USD +182%
Operating Income (Loss) 153M USD
Nonoperating Income (Expense) 10.6M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 164M USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent 164M USD
Earnings Per Share, Basic 4.22 USD/shares
Earnings Per Share, Diluted 4.22 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.44M USD
Assets, Current 4.02M USD +579%
Property, Plant and Equipment, Net 282K USD
Operating Lease, Right-of-Use Asset 1.4M USD
Other Assets, Noncurrent 29K USD
Assets 5.73M USD -73.7%
Accounts Payable, Current 3.03M USD
Employee-related Liabilities, Current 1.25M USD
Liabilities, Current 10.4M USD +10.2%
Operating Lease, Liability, Noncurrent 1.26M USD
Liabilities 33.7M USD +179%
Retained Earnings (Accumulated Deficit) -428M USD -3619%
Stockholders' Equity Attributable to Parent -153M USD +46.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -27.9M USD +90.2%
Liabilities and Equity 5.73M USD -73.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.6M USD +22.2%
Net Cash Provided by (Used in) Financing Activities 5M USD -16.7%
Net Cash Provided by (Used in) Investing Activities 260M USD
Common Stock, Shares Authorized 500M shares
Common Stock, Shares, Issued 39.1M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.6M USD +28.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.44M USD +32.2%
Deferred Tax Assets, Valuation Allowance 54M USD +17.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 54.1M USD +17.3%
Operating Lease, Liability 1.4M USD
Lessee, Operating Lease, Liability, to be Paid 1.58M USD
Property, Plant and Equipment, Gross 502K USD
Operating Lease, Liability, Current 134K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 175K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 159K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 188K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 297K USD
Deferred Tax Assets, Operating Loss Carryforwards 28.6M USD +42.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 14.7M USD +32.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 307K USD
Operating Lease, Payments 80K USD +208%
Additional Paid in Capital 32K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 25K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 153K USD -32.6%
Share-based Payment Arrangement, Expense 1.7M USD +54.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%